Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 1520858
PUBLISHER: GlobalData | PRODUCT CODE: 1520858
United Kingdom Cardiac Rhythm Management Devices Market Outlook to 2033 - Cardiac Resynchronisation Therapy (CRT), Implantable Cardioverter Defibrillators (ICD) and Others
PUBLISHED:
PAGES: 44 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
GlobalData's "United Kingdom Cardiac Rhythm Management Devices Market Outlook to 2033" is a comprehensive databook report, covering key market data on the Cardiac Rhythm Management Devices market. The databook report provides value (USD), volume (units) and average prices (USD) - Cardiac Resynchronisation Therapy (CRT), Implantable Cardioverter Defibrillators (ICD) and Others.
The United Kingdom Cardiac Rhythm Management Devices Market report provides key information and data on -
- Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
- 2023 company share and distribution share data for Cardiac Rhythm Management Devices Market.
- Global corporate-level profiles of key companies operating within the Cardiac Rhythm Management Devices Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.
Scope
United Kingdom Cardiac Rhythm Management Devices is segmented as follows -
- Cardiac Resynchronisation Therapy (CRT)
- Pacemakers
- Implantable Cardioverter Defibrillators (ICD)
- Implantable Loop Recorders (ILR)
Reasons to Buy
The United Kingdom Cardiac Rhythm Management Devices Market report helps you to develop -
- Business strategies by identifying the key market segments poised for strong growth in the future.
- Market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- Understand the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.
Product Code: GDME0188CCDB
Table of Contents
1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2 Introduction
- 2.1 What Is This Report About?
- 2.2 Cardiac Rhythm Management Devices Market Segmentation
- 2.3 Definitions of Markets Covered in the Report
3 Cardiac Rhythm Management Devices Market, United Kingdom
- 3.1 Cardiac Rhythm Management Devices Market, United Kingdom, Revenue ($m), 2018-2033
- 3.1.1 Cardiac Resynchronisation Therapy (CRT) Market, United Kingdom, Revenue ($m), by Segment, 2018-2033
- 3.1.2 Implantable Cardioverter Defibrillators (ICD) Market, United Kingdom, Revenue ($m), by Segment, 2018-2033
- 3.1.3 Pacemakers Market, United Kingdom, Revenue ($m), by Segment, 2018-2033
- 3.2 Cardiac Rhythm Management Devices Market, United Kingdom, Volume (Units), 2018-2033
- 3.2.1 Cardiac Resynchronisation Therapy (CRT) Market, United Kingdom, Volume (Units), by Segment, 2018-2033
- 3.2.2 Implantable Cardioverter Defibrillators (ICD) Market, United Kingdom, Volume (Units), by Segment, 2018-2033
- 3.2.3 Pacemakers Market, United Kingdom, Volume (Units), by Segment, 2018-2033
- 3.3 Cardiac Rhythm Management Devices Market, United Kingdom, Average Price ($), 2018-2033
- 3.4 Cardiac Rhythm Management Devices Market, United Kingdom, Distribution Share by Revenue ($m), 2023
- 3.5 Cardiac Rhythm Management Devices Market, United Kingdom, Company Share by Revenue ($m), 2023
4 Overview of Key Companies in United Kingdom, Cardiac Rhythm Management Devices Market
- 4.1 Medtronic Plc
- 4.1.1 Company Overview
- 4.2 Abbott Laboratories
- 4.2.1 Company Overview
- 4.3 Boston Scientific Corp
- 4.3.1 Company Overview
- 4.4 Biotronik SE & Co KG
- 4.4.1 Company Overview
- 4.5 MicroPort Scientific Corp
- 4.5.1 Company Overview
5 Cardiac Rhythm Management Devices Market Pipeline Products
6 Financial Deals Landscape
- 6.1 Debt Offerings
- 6.1.1 LivaNova Prices USD300 Million in Priavte Placement of 2.50% Convertible Senior Notes Due 2029
7 Recent Developments
- 7.1 Corporate Communications
- 7.1.1 Jun 18, 2024: Aviva McPherron Joins Orthofix as President of Global Operations and Quality
- 7.1.2 Apr 30, 2024: LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
- 7.1.3 Sep 21, 2023: LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023
- 7.2 Financial Announcements
- 7.2.1 Jan 31, 2024: Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
- 7.2.2 Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
- 7.2.3 Aug 25, 2023: Blackford and Ligence Announce Echocardiography AI Partnership
8 Appendix
- 8.1 Research Methodology
- 8.1.1 Coverage
- 8.1.2 Secondary Research
- 8.1.3 Primary Research
- 8.1.4 Market Modeling and Forecasting
- 8.1.5 Company Share Analysis
- 8.1.6 Distribution Share Analysis
- 8.1.7 Benchmarking
- 8.2 GlobalData Consulting
- 8.3 Contact Us
- 8.4 Disclaimer
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.